# A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)

> **NCT01054443** · PHASE2 · TERMINATED · sponsor: **Shionogi** · enrollment: 20 (actual)

## Conditions studied

- Immune Thrombocytopenia (ITP)

## Interventions

- **DRUG:** Placebo
- **DRUG:** Lusutrombopag

## Key facts

- **NCT ID:** NCT01054443
- **Lead sponsor:** Shionogi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-03-18
- **Primary completion:** 2010-11-24
- **Final completion:** 2010-11-24
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** This study was terminated before the planned sample size was enrolled because results indicated that a higher dose was necessary to elicit an efficacy effect.
- **Last updated:** 2021-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01054443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01054443, "A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01054443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*